QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 apogee-therapeutics-highlights-apg333-phase-1-results-supporting-combination-development-with-apg777-for-respiratory-diseases

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed...

 craig-hallum-initiates-coverage-on-apogee-therapeutics-with-buy-rating-announces-price-target-of-109

Craig-Hallum analyst Adam Vogel initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Pric...

 rbc-capital-maintains-outperform-on-apogee-therapeutics-raises-price-target-to-70

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and raises the price target...

 mizuho-initiates-coverage-on-apogee-therapeutics-with-outperform-rating-announces-price-target-of-105

Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Outperform rating and announc...

 btig-reiterates-buy-on-apogee-therapeutics-maintains-115-price-target

BTIG analyst Julian Harrison reiterates Apogee Therapeutics (NASDAQ:APGE) with a Buy and maintains $115 price target.

 rbc-capital-initiates-coverage-on-apogee-therapeutics-with-outperform-rating-announces-price-target-of-60

RBC Capital analyst Brian Abrahams initiates coverage on Apogee Therapeutics (NASDAQ: APGE) with a Outperform rating and ann...

 apogee-therapeutics-says-data-from-phase-2-apex-trial-of-apg777-for-moderate-to-severe-atopic-dermatitis-accepted-for-late-breaker-oral-presentation-at-upcoming-eadv-congress-2025

Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with pote...

 b-of-a-securities-maintains-buy-on-apogee-therapeutics-raises-price-target-to-87

B of A Securities analyst Tim Anderson maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target fr...

 apogee-therapeutics-q2-eps-113-beats-116-estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION